NASDAQ:MRNS

Marinus Pharmaceuticals Stock Forecast, Price & News

$17.84
-0.91 (-4.85 %)
(As of 06/15/2021 03:02 PM ET)
Add
Compare
Today's Range
$17.18
$18.61
50-Day Range
$13.73
$18.75
52-Week Range
$6.04
$20.04
Volume16,647 shs
Average Volume198,263 shs
Market Capitalization$653.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
30 days | 90 days | 365 days | Advanced Chart
Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Marinus Pharmaceuticals logo

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.59 out of 5 stars

Medical Sector

442nd out of 2,100 stocks

Pharmaceutical Preparations Industry

213th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

Is Marinus Pharmaceuticals a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Marinus Pharmaceuticals stock.
View analyst ratings for Marinus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Marinus Pharmaceuticals?

Wall Street analysts have given Marinus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Marinus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Marinus Pharmaceuticals
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its earnings results on Monday, May, 17th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.28. The biopharmaceutical company earned $1.81 million during the quarter, compared to analyst estimates of $2.61 million.
View Marinus Pharmaceuticals' earnings history
.

How has Marinus Pharmaceuticals' stock price been impacted by Coronavirus?

Marinus Pharmaceuticals' stock was trading at $6.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRNS stock has increased by 166.6% and is now trading at $17.49.
View which stocks have been most impacted by COVID-19
.

When did Marinus Pharmaceuticals' stock split? How did Marinus Pharmaceuticals' stock split work?

Marinus Pharmaceuticals shares reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of Marinus Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for MRNS?

10 equities research analysts have issued twelve-month price objectives for Marinus Pharmaceuticals' shares. Their forecasts range from $20.00 to $38.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $29.11 in the next year. This suggests a possible upside of 66.4% from the stock's current price.
View analysts' price targets for Marinus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the following people:
  • Dr. Scott N. Braunstein, CEO, Pres & Director (Age 58, Pay $898.88k)
  • Mr. Edward F. Smith CPA, Consultant (Age 50, Pay $570.09k)
  • Dr. Joseph Hulihan M.D., Chief Medical Officer (Age 65, Pay $488.87k)
  • Mr. Steven E. Pfanstiel C.M.A., M.B.A., CFO & Treasurer (Age 48)
  • Ms. Sasha Damouni Ellis, VP of Investor Relations & Corp. Communications
  • Ms. Martha E. Manning, VP, Gen. Counsel & Sec. (Age 66)
  • Mr. Thomas J. Lyons, VP of Corp., Bus. Devel. & Commercial Planning
  • Ms. Lisa Lejuwaan, VP of Sales
  • Ms. Rose McKinley, VP of HR & Organizational Devel.
  • Dr. Alex Aimetti, Head of Scientific Affairs

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.44%), 683 Capital Management LLC (5.17%), Suvretta Capital Management LLC (4.99%), Bleichroeder LP (2.27%), Alyeska Investment Group L.P. (1.72%) and Geode Capital Management LLC (1.38%). Company insiders that own Marinus Pharmaceuticals stock include Edward F Smith and Scott Braunstein.
View institutional ownership trends for Marinus Pharmaceuticals
.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Squarepoint Ops LLC, Citigroup Inc., AQR Capital Management LLC, Alliancebernstein L.P., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Marinus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Suvretta Capital Management LLC, Scion Asset Management LLC, Goldman Sachs Group Inc., Geode Capital Management LLC, Bleichroeder LP, 683 Capital Management LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Marinus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $17.49.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals has a market capitalization of $640.66 million and generates $1.72 million in revenue each year. The biopharmaceutical company earns $-67,470,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

Marinus Pharmaceuticals employs 65 workers across the globe.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is www.marinuspharma.com.

Where are Marinus Pharmaceuticals' headquarters?

Marinus Pharmaceuticals is headquartered at 100 Matsonford Rd Suite 500, Radnor PA, 19087.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.